Agomab Therapeutics reaches 716 million dollar valuation despite share drop in Nasdaq debut
Belgian biotech Agomab saw its shares fall eight percent during its Friday Nasdaq debut. The firm raised 200 million dollars despite selective investor demand.
Insights:
Agomab Therapeutics completed its $200 million U.S. 
US initial public offering today, February 6, 2026, marking its debut on the Nasdaq. The clinical-stage biopharmaceutical firm sold 12.5 million American Depositary Shares at an offer price of $16, a figure that fell within the marketed range of $15 to $17. Upon entering the public market, the shares opened at $14.70, representing a decline of approximately 8% from the offer price and resulting in a company valuation of $716.4 million.
US initial public offering today, February 6, 2026, marking its debut on the Nasdaq. The clinical-stage biopharmaceutical firm sold 12.5 million American Depositary Shares at an offer price of $16, a figure that fell within the marketed range of $15 to $17. Upon entering the public market, the shares opened at $14.70, representing a decline of approximately 8% from the offer price and resulting in a company valuation of $716.4 million.
